DOI: 10.36347/sjams.2015.v03i09.035

Pages: 3325-3328

This study was performed in 100 patients receiving first-line highly active antiretroviral therapy (HAART) through the National AIDS Control Programme of India in May-July 2013 at ART centre PGIMS Rohtak (Haryana). The patients were followed for six month for analysing the immune response and toxicity profile of first line antiretroviral therapy. Of the 100 patients the median CD4 count of enrolled patients was 233.33±151 cells/ cumm at treatment initiation; 14% had baseline CD4 count <100 cells/ cmm. Of the 100 patients 91% were alive after 6 months. The mean CD4 count of the cohort was increased from 233.33±151 cells/cumm to 434.8 ± 217cells/cumm at six month, (P < 0.0001). Mean weight increased from 48.9 ± 10 Kg to 57 ± 10.7 Kg, Mean BMI increased from 22.2 ± 4 Kg/m2 to 25.9 ± 4 .3 Kg/m2 and Mean haemoglobin increased from 10.6 ± 2 gm% to 12.8 ± 1.2 gm%. The rise was statistically significant (P < 0.0001). The side effects of HAART were reported in 70 % of the patients. The most common toxicity reported in our study was nausea and vomiting (59 %), followed by Anemia (15 %), Hepatotoxicity (3%), and Hyper pigmenation (11 %), Neurological (8 %) Oral ulcers (10 %), Peripheral neuropathy (4%), Rash (9%). which were usually self resolving or reversed after withdrawing of the offending agents. We concluded from the study that the first line HAART is efficacious and well tolerated.